Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue is expected to exceed the initial forecast, driven by higher sales of high-priced pharmaceuticals and influenza vaccines. Operating profit and ordinary profit are expected to fall short of the previous forecast, however, due to drug price revisions, lower selling prices resulting from intensified market competition, higher purchase prices, lower rebates, a lower gross profit margin, increased personnel and selling, general and administrative expenses, and higher upfront investment in digital transformation and other initiatives and cybersecurity costs.
| Item | Details |
|---|---|
| Net Sales | 620,000 Million yen → 627,000 Million yen（+1.1%） |
| Operating profit | 4,100 Million yen → 1,800 Million yen（-56.1%） |
| Ordinary income | 5,000 Million yen → 2,700 Million yen（-46.0%） |
| Profit attributable to owners of the parent | 7,500 Million yen → 6,700 Million yen（-10.7%） |
| Net income per share | 155.03 yen/sen → 138.50 yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Revenue ¥610,497 million, core operating profit ¥5,307 million, operating profit ¥4,027 million, ordinary profit ¥7,822 million, net income attributable to owners of the parent ¥7,362 million, and basic earnings per share ¥152.29 (fiscal year ended March 2026) |
| Reason for the revision | Revenue is expected to exceed the initial forecast, driven by higher sales of high-priced pharmaceuticals and influenza vaccines. Operating profit and ordinary profit are expected to fall short of the previous forecast, however, due to drug price revisions, lower selling prices resulting from intensified market competition, higher purchase prices, lower rebates, a lower gross profit margin, increased personnel and selling, general and administrative expenses, and higher upfront investment in digital transformation and other initiatives and cybersecurity costs. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to exceed the previous forecast, driven by higher sales of high-priced pharmaceuticals, particularly anticancer drugs, and influenza vaccines. Profit is expected to fall short, however, due to drug price revisions, lower selling prices resulting from intensified market competition, higher purchase prices, lower rebates, and higher personnel and selling, general and administrative expenses, as well as increased costs for promoting digital transformation and cybersecurity measures.